_1777294237270_124456903.png&w=48&q=75){kind=small}
Fawanda Yo weight loss approved
The General Authority for Food and Drug issued its approval for the registration of the product "Fondaio" to help with weight loss and to maintain long-term results in adults who are obese or overweight with related medical conditions. This decision came after a comprehensive evaluation of its efficacy and safety. The product contains the active ingredient Orforglebore and works by activating glucagon-like peptide-1 receptors, which reduces appetite and helps decrease food intake. Studies have shown that a dose of 36 mg of "Fondaio" led to an average weight reduction of up to 11.2% in cases of obesity without diabetes, and 9.6% in diabetic patients over 72 weeks. The medication is to be taken orally once daily and should be used in conjunction with a healthy diet and physical activity, with medical follow-up due to the potential for gastrointestinal disturbances and other side effects. Its use is prohibited for individuals with a history of thyroid tumors or hereditary syndromes related to such conditions.
Notice: This Is an AI-Generated Summary
Comments (0)